JSH-23-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•Agonists•ScreeningLibrarieswww.MedChemEJSH-23Cat.No.:HY-13982CASNo.:749886-87-1分⼦式:C₁₆H₂₀N₂分⼦量:240.34作⽤靶点:NF-κB作⽤通路:NF-κB储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:≥56mg/mL(233.00mM)扫描⼆维码，*"≥"meanssoluble,butsaturationunknown.运⽤溶解⽅案计算器获得适合您实验体系的溶解⽅案MassSolvent1mg5mg10mgConcentration制备储备液1mM4.1608mL20.8039mL41.6077mL5mM0.8322mL4.1608mL8.3215mL10mM0.4161mL2.0804mL4.1608mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存⽅式和期限。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶1.请依序添加每种溶剂：10%DMSO40%PEG3005%Tween-8045%salineSolubility:≥2.5mg/mL(10.40mM);Clearsolution此⽅案可获得≥2.5mg/mL(10.40mM，饱和度未知)的澄溶液。以1mL⼯作液为例，取100μL25.0mg/mL的澄DMSO储备液加到400μLPEG300中，混合均匀；向上述体系中加⼊50μLTween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。1/3www.MedChemEwww.MedChemE2.请依序添加每种溶剂：10%DMSO90%cornoilSolubility:≥2.5mg/mL(10.40mM);Clearsolution此⽅案可获得≥2.5mg/mL(10.40mM，饱和度未知)的澄溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以1mL⼯作液为例，取100μL25.0mg/mL的澄DMSO储备液加到900μL⽟⽶油中，混合均匀。BIOLOGICALACTIVITY⽣物活性JSH-23NF-κB抑制剂，作⽤于脂多糖刺激的巨噬细胞RAW264.7，抑制NF-κB转录活性，IC50为7.1μM。JSH-23抑制NF-κBp65的核易位⽽不响IκBα降解[1]。IC50&TargetNF-κB7.1μM(IC50,inRAW264.7cells)体外研究JSH-2(1-300μM;24hours)at<100μMdoesnotshowsignificantcytotoxiceffectsontheRAW264.7cells[1].NuclearamountofNF-κBp65ismarkedlyincreaseduponexposuretoLPSfor1h.TreatmentofJSH-23(30μM;1hours)toLPS-stimulatedRAW264.7cellsdecreasesnuclearcontentofNF-κBp65inadose-dependentmanner[1].CellCytotoxicityAssay[1]CellLine:MacrophagesRAW264.7Concentration:1,3,10,30,100,300μMIncubationTime:24hoursResult:Didnotshowsignificantcytotoxiceffectsat<100μM.WesternBlotAnalysis[1]CellLine:MacrophagesRAW264.7withLPS-stimulatedConcentration:30μMIncubationTime:1hourResult:DecreasednuclearcontentofNF-κBp65inadose-dependentmanner,correspondingto49±4%inhibitionat3μM,75±7%at10μMand95±8%at30μM.体内研究JSH-23(1mg/kg,3mg/kg;orallyadministered;daily;for2weeks)significantlyreversesthenerveconductionandnervebloodflowdeficitsseenindiabeticrats[1].AnimalModel:MaleSpragueDawleydiabeticrats(250-270g)[1]Dosage:1mg/kg,3mg/kg2/3www.MedChemEwww.MedChemEAdministration:Orallyadministered;daily;for2weeksResult:Producedsignificantimprovementinmotornerveconductionvelocity(MNCV).户使⽤本产品发表的科研⽂献•SciTranslMed.2019Feb6;11(478).pii:eaau5266.•CancerLett.2018Aug1;428:77-89.•JInvestDermatol.2019Jan;139(1):224-234.•MolTher-NuclAcids.2021Mar13.•EBioMedicine.2019May;43:188-200.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].ShinHM,etal.Inhibitoryactionofnovelaromaticdiaminecompoundonlipopolysaccharide-inducednucleartranslocationofNF-kappaBwithoutaffectingIkappaBdegradation.FEBSLett.2004Jul30;571(1-3):50-4.[2].KumarA,etal.JSH-23targetsnuclearfactor-kappaBandreversesvariousdeficitsinexperimentaldiabeticneuropathy:effectonneuroinflammationandantioxidantdefence.DiabetesObesMetab.2011Aug;13(8):750-8.McePdfHeight关注MCE中国公众号，

获取前沿资讯、最新活动和

实⽤科研⼯具MedChemExpress(MCE)只为有资质的科研机构、医药企业基于科学研究或药证申报的⽤途提供医药研发服务